Neptune, the Next Pluto?-Durvalumab and Tremelimumab Face Challenges in Entering the NSCLC Space

Affiliations

¹ Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California; Department of Medicine, University of California Irvine School of Medicine, Orange, California.
² Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California; Department of Medicine, University of California Irvine School of Medicine, Orange, California; St. Marianna University School of Medicine, Kawasaki, Japan. Electronic address: nagasakm@hs.uci.edu.

Free article

Editorial

Jeffrey Y Ahn et al. J Thorac Oncol. 2023 Jan.

Free article

. 2023 Jan;18(1):29-30.

doi: 10.1016/j.jtho.2022.11.004.

¹ Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California; Department of Medicine, University of California Irvine School of Medicine, Orange, California.
² Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California; Department of Medicine, University of California Irvine School of Medicine, Orange, California; St. Marianna University School of Medicine, Kawasaki, Japan. Electronic address: nagasakm@hs.uci.edu.

No abstract available

Comment on

NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
de Castro G Jr, Rizvi NA, Schmid P, Syrigos K, Martin C, Yamamoto N, Cheng Y, Moiseyenko V, Summers Y, Vynnychenko I, Lee SY, Bryl M, Zer A, Erman M, Timcheva C, Raja R, Naicker K, Scheuring U, Walker J, Mann H, Chand V, Mok T; NEPTUNE Investigators. de Castro G Jr, et al. J Thorac Oncol. 2023 Jan;18(1):106-119. doi: 10.1016/j.jtho.2022.09.223. Epub 2022 Oct 12. J Thorac Oncol. 2023. PMID: 36240972 Clinical Trial.